User Reviews for Gemtuzumab
Also known as: Mylotarg
Reviews may be moderated or edited before publication to correct grammar and spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest in the medication will not be published. As reviews and ratings are subjective and self-reported, this information should not be used as the basis for any statistical analysis or scientific studies.
Mylotarg (gemtuzumab) for Acute Myeloid Leukemia: “This is a medicine suggested for my sister who has only a few weeks to live. Will know tomorrow if Dr goes through with this. So scary. He did mentioned about it being taken off the market and now back available. How does one choose?”
Mylotarg (gemtuzumab) for Acute Myeloid Leukemia: “This medicine should be taken off the market. It caused more harm than good. My mother died because of incompetent doctors and Mylotarg. Nothing was changed about the ingredients/composition of this medicine after the FDA approved it to be brought BACK on the market after being taken off for TEN years. It was taken off because it killed more than it saved. Just like it is still doing. The only thing about this medicine that changed when it was brought back in late 2017 was the dosage and how it is administered.”
This information is NOT intended to endorse any particular medication. While these reviews might be helpful, they are not a substitute for the expertise, knowledge and judgement of healthcare practitioners.
More about gemtuzumab
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- 2 Reviews
- Drug class: CD33 monoclonal antibodies
Other brands: Mylotarg